Defibrotide sodium

(Defitelio®)

Defitelio®

Drug updated on 11/13/2023

Dosage FormInjection (intravenous; 200 mg/2.5 mL)
Drug ClassOligonucleotides
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

Product Monograph / Prescribing Information

Document TitleYearSource
Defitelio (defibrotide sodium) Prescribing Information.2022Jazz Pharmaceuticals, Inc. Palo Alto, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines